AC
ACMR.DH
—
—
Pharmaceuticals
Acmr.Dh
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
4,61 %
Op margin
18,9 %
ROE
9,1 %
Net margin
6,8 %
Debt / equity
0,93
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$78,65
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
ACMR.DH is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription and over-the-counter medications.
Business. ACMR.DH is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription and over-the-counter medications.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY7 analysts
6 buy1 hold0 sell
Avg 12m price target70,60
Analyst recommendations
7 analysts · consensus BuyBuy6
Hold1
Sell0
12-month price target
70,60
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
7 analysts · indicative
Ownership→
JANUS HENDERSON GROUP PLC
largest disclosed fund holder
Profitability→
9,1 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ACMR.DH. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
ACMR.DH is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription and over-the-counter medications.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI synthesis
GENERATEDACMR.DH maintains a debt-to-equity ratio of 0.93, indicating a moderate reliance on debt financing, and a current ratio of 1.15, suggesting limited short-term liquidity cushion. The company's free cash flow of 479 million BDT is constrained by capital expenditures of 3.08 billion BDT, which may reflect ongoing investment in production or R&D. The return on equity of 9.08% and return on assets of 4.16% suggest that the company is generating returns above the industry median for ROE but below for ROA, indicating room for improvement in asset utilization.
Profitability metrics show that ACMR.DH has a gross profit margin of 42.26% and an operating margin of 18.86%, both of which are in line with the industry median for pharmaceutical firms. However, the net profit margin of 6.76% is slightly below the median, potentially due to higher operating expenses or tax burdens. The company's operating income of 6.78 billion BDT and net income of 2.43 billion BDT reflect a strong core business, but the net cash position is negative after subtracting total debt, signaling potential liquidity constraints.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts, which could impact revenue stability. The absence of segment or geographic breakdown in the financial data limits the ability to assess risk distribution across product lines or markets.
ACMR.DH's revenue growth trajectory is not explicitly provided, but the company's operating cash flow of 3.18 billion BDT and free cash flow of 479 million BDT suggest a stable, though not rapidly growing, business. The capital expenditure of 3.08 billion BDT indicates ongoing investment, which may support future growth but could also pressure near-term cash flow. Analysts reported a last actual revenue of 26.95 billion BDT, which is lower than the full-year revenue of 35.94 billion BDT, suggesting a possible seasonal or quarterly fluctuation.
The risk assessment highlights medium liquidity risk and low dilution risk. The company's net cash position is negative after subtracting total debt, which could limit its ability to fund operations or investments without external financing. However, the dilution risk is low, and no recent dilutive events are reported, suggesting a stable capital structure. The absence of dilution sources in the risk assessment implies that ACMR.DH has not issued new shares recently or disclosed plans for future share offerings.
Recent events include the filing of financial data for the latest fiscal year, which shows a strong revenue and profit performance. The company's last actual EPS of 10.89 BDT and revenue of 26.95 billion BDT indicate a solid earnings report, though the full-year revenue of 35.94 billion BDT suggests a more comprehensive view of the company's financial health. No additional filings or transcripts are available to provide further insight into the company's strategic direction or operational performance.
Key takeaways
- ACMR.DH has a strong operating income and net income, but its net cash position is negative after subtracting total debt.
- The company's return on equity is above the industry median, but its return on assets is below, indicating potential inefficiencies in asset use.
- ACMR.DH's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company's liquidity risk is medium, and its dilution risk is low, suggesting a stable capital structure.
- Capital expenditures are significant, which may support future growth but could pressure near-term cash flow.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
—
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$26.74B
Net cashⓘ
-$24.92B
Current ratioⓘ
1.1
Debt / equityⓘ
0.9
ROAⓘ
4.2%
ROEⓘ
9.1%
Cash conversionⓘ
131.0%
CapEx / revenueⓘ
-8.6%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships14 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries14
EX21:05a4960c9709EX21:05a4960c9709Subsidiarie97%
EX21:111b36876402EX21:111b36876402Subsidiarie97%
EX21:17a18a701837EX21:17a18a701837Subsidiarie97%
EX21:3e3d344ddf8aEX21:3e3d344ddf8aSubsidiarie97%
EX21:50fb2c0662afEX21:50fb2c0662afSubsidiarie97%
EX21:57c1d3a07481EX21:57c1d3a07481Subsidiarie97%
EX21:7e101084e7d3EX21:7e101084e7d3Subsidiarie97%
EX21:80e90a112f0eEX21:80e90a112f0eSubsidiarie97%
EX21:9192150e2f66EX21:9192150e2f66Subsidiarie97%
EX21:be84206d2671EX21:be84206d2671Subsidiarie97%
EX21:bf6f6db053adEX21:bf6f6db053adSubsidiarie97%
EX21:c0c36523108fEX21:c0c36523108fSubsidiarie97%
EX21:ecf30e84d646EX21:ecf30e84d646Subsidiarie97%
EX21:fd0425ac4d19EX21:fd0425ac4d19Subsidiarie97%
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
1,79
Predicted surprise
+0,00
Beat probability
45 %
Analysts
7
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-08-02 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$66,00
Mean$70,60
Median$68,00
High$82,00
Spot—
12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin18,9 %Above P75
Net Margin6,8 %Above median
ROE9,1 %Above median
Capex / Rev-8,6 %Below median
D/E0,93Bottom quartile
Cash Conv1,31Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 17 697 sh33 exercises · 4 grants9 insiders
- See remarks · Stock Option → Class A Common StockDisposed 5 399 @ $13,89exercise · 2026-06-05
- Director, See Remarks, 10% owner · Stock Option → Class A Common StockDisposed 40 002 @ $1,00exercise · 2026-06-04
- See remarks · Stock Option → Class A Common StockDisposed 13 351 @ $13,89exercise · 2026-06-04
- Director, See Remarks, 10% owner · Stock Option → Class A Common StockDisposed 60 000 @ $1,00exercise · 2026-06-03
- Director · Stock Option → Class A Common StockDisposed 5 000 @ $5,60exercise · 2026-05-19
- Director, See Remarks, 10% owner · Restricted Stock Units → Class A Common StockAcquired 6 208grant · 2026-05-13
- Director · Stock Option → Class A Common StockDisposed 5 000 @ $29,18exercise · 2026-04-17
- See Remarks · Stock Option → Class A Common StockDisposed 60 000 @ $13,89exercise · 2026-03-12
- See Remarks · Stock Option → Class A Common StockDisposed 38 551 @ $19,49exercise · 2026-03-12
- Director, See Remarks, 10% owner · Stock Option → Class A Common StockDisposed 50 000 @ $1,00exercise · 2026-03-12
- Director, See Remarks, 10% owner · Stock Option → Class A Common StockDisposed 60 000 @ $1,00exercise · 2026-03-11
- Director · Stock Option → Class A Common StockDisposed 15 000 @ $1,00exercise · 2026-03-11
- Director · Stock Option → Class A Common StockDisposed 45 000 @ $1,00exercise · 2026-03-10
- Director · Stock Option → Class A Common StockDisposed 5 000 @ $5,60exercise · 2026-03-09
- See remarks · Stock Option → Class A Common StockDisposed 15 000 @ $4,55exercise · 2026-03-06
- Director · Stock Option → Class A Common StockDisposed 5 000 @ $29,18exercise · 2026-03-05
- See remarks · Stock Option → Class A Common StockDisposed 15 000 @ $4,55exercise · 2026-03-05
- Director, See Remarks, 10% owner · Stock Option → Class A Common StockAcquired 545 400 @ $7,36grant · 2026-02-04
- See Remarks · Stock Option → Class A Common StockDisposed 22 500 @ $25,45exercise · 2025-12-08
- Director, See Remarks, 10% owner · Stock Option → Class A Common StockDisposed 60 000 @ $1,00exercise · 2025-12-04
- See Remarks · Stock Option → Class A Common StockDisposed 8 750 @ $4,55exercise · 2025-12-04
- Director, See Remarks, 10% owner · Stock Option → Class A Common StockDisposed 70 000 @ $1,00exercise · 2025-12-03
- See remarks · Stock Option → Class A Common StockDisposed 20 000 @ $1,77exercise · 2025-12-03
- See remarks · Stock Option → Class A Common StockDisposed 100 000 @ $1,77exercise · 2025-12-02
- See remarks · Stock Option → Class A Common StockDisposed 15 000 @ $5,60exercise · 2025-11-13
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
Source documents
- ACMR.DH Market data — financials · 2026-05-27
- ACME Laboratories Ltd Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,02 %$43M
- Investment Managers · as of 2026-03-310,01 %$15M
- Investment Managers · as of 2026-03-310,01 %$13M
- Investment Managers · as of 2026-03-310,01 %$28M
- Investment Managers · as of 2026-03-310,01 %$13M
- Funds · as of 2026-03-310,00 %$31M
- Investment Managers · as of 2026-03-310,00 %$54M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$22M
- Investment Managers · as of 2026-03-310,00 %$19M
- Investment Managers · as of 2026-03-310,00 %$22M
- Investment Managers · as of 2025-12-310,00 %$196M
- Investment Managers · as of 2026-03-310,00 %$47M
- Investment Managers · as of 2026-03-310,00 %$16M
- Investment Managers · as of 2026-03-310,00 %$79M
- Investment Managers · as of 2026-03-310,00 %$5M
- Institutional Investor · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2024-06-300,00 %$94M
- Institutional Investor · as of 2026-03-310,00 %$8M
- Brokerage Firms · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$25M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2024-12-310,00 %$2M
- Brokerage Firms · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Net selling0 buys · 66 sellsnet -$43,4M9 insiders · last 365d
- See remarks · Class A Common StockSold 2 384 @ $81,73$195K · 2026-06-05
- See remarks · Class A Common StockSold 968 @ $82,61$80K · 2026-06-05
- See remarks · Class A Common StockSold 400 @ $84,01$34K · 2026-06-05
- See remarks · Class A Common StockSold 1 647 @ $85,41$141K · 2026-06-05
- See remarks · Class A Common StockOther 5 399 @ $13,89$75K · 2026-06-05
- See remarks · Class A Common StockSold 2 839 @ $85,77$244K · 2026-06-04
- See remarks · Class A Common StockOther 13 351 @ $13,89$185K · 2026-06-04
- See remarks · Class A Common StockSold 1 300 @ $84,08$109K · 2026-06-04
- See remarks · Class A Common StockSold 9 212 @ $85,11$784K · 2026-06-04
- Director, See Remarks, 10% owner · Class A Common StockOther 40 002 @ $1,00$40K · 2026-06-04
- Director, See Remarks, 10% owner · Class A Common StockSold 2 060 @ $83,86$173K · 2026-06-04
- Director, See Remarks, 10% owner · Class A Common StockSold 17 543 @ $85,11$1,5M · 2026-06-04
- Director, See Remarks, 10% owner · Class A Common StockSold 10 992 @ $86,07$946K · 2026-06-04
- Director, See Remarks, 10% owner · Class A Common StockSold 8 581 @ $87,13$748K · 2026-06-04
- Director, See Remarks, 10% owner · Class A Common StockSold 826 @ $87,91$73K · 2026-06-04
- Director, See Remarks, 10% owner · Class A Common StockSold 32 450 @ $89,84$2,9M · 2026-06-03
- Director, See Remarks, 10% owner · Class A Common StockSold 9 925 @ $90,78$901K · 2026-06-03
- Director, See Remarks, 10% owner · Class A Common StockSold 4 300 @ $87,57$377K · 2026-06-03
- Director, See Remarks, 10% owner · Class A Common StockSold 1 187 @ $93,04$110K · 2026-06-03
- Director, See Remarks, 10% owner · Class A Common StockSold 5 843 @ $92,38$540K · 2026-06-03
- Director, See Remarks, 10% owner · Class A Common StockOther 60 000 @ $1,00$60K · 2026-06-03
- Director, See Remarks, 10% owner · Class A Common StockSold 6 295 @ $88,98$560K · 2026-06-03
- Director · Class A Common StockSold 500 @ $65,09$33K · 2026-05-19
- Director · Class A Common StockSold 1 858 @ $67,54$125K · 2026-05-19
- Director · Class A Common StockSold 1 333 @ $63,84$85K · 2026-05-19
Short positioning
3.9Mshares short+20.5% vs prior
2.85days to cover
52.7%short of daily vol
959fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ACMR.DHCanonical
— · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 61.9%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 15.2%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 37.5%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -27.5%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -106.8%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -9.2%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 42.7%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 2.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 23.9%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -10.5%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -12.0%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 28.3%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 85.9%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -31.7%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.64xDerived (calculated)
- Current ratio (FY 2025-12-31): 3.27xDerived (calculated)
- Return on assets (FY 2025-12-31): 3.3%Derived (calculated)
- Return on equity (FY 2025-12-31): 6.4%Derived (calculated)
- Gross margin (FY 2025-12-31): 44.4%Derived (calculated)
- Net margin (FY 2025-12-31): 10.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 54.8%Derived (calculated)
- Current liabilities (annual): USD 745.71MSEC XBRL filing
- Long-term debt (annual): USD 214.01MSEC XBRL filing
- Current assets (annual): USD 2.44BSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-05 00:00 UTCINSIDER26 insider transactions — 2026-06 · net sell $10.1M 4 derivative
2026-06-05INSIDERCheav Sotheara sold 968 sh Class A Common Stock — See remarks ~$80k
2026-06-05INSIDERCheav Sotheara sold 1.6k sh Class A Common Stock — See remarks ~$141k
2026-06-05INSIDERCheav Sotheara transacted 5.4k sh Class A Common Stock — See remarks ~$75k
2026-06-05INSIDERCheav Sotheara sold 2.4k sh Class A Common Stock — See remarks ~$195k
2026-06-05INSIDERCheav Sotheara sold 400 sh Class A Common Stock — See remarks ~$34k
2026-06-05INSIDERCheav Sotheara disposed of 5.4k sh Stock Option — See remarks
2026-06-04INSIDERCheav Sotheara sold 2.8k sh Class A Common Stock — See remarks ~$244k
2026-06-04INSIDERCheav Sotheara transacted 13.4k sh Class A Common Stock — See remarks ~$185k
2026-06-04INSIDERCheav Sotheara sold 1.3k sh Class A Common Stock — See remarks ~$109k
2026-06-04INSIDERCheav Sotheara sold 9.2k sh Class A Common Stock — See remarks ~$784k
2026-06-04INSIDERWang David H transacted 40.0k sh Class A Common Stock — Director, See Remarks, 10% owner ~$40k
2026-06-04INSIDERWang David H sold 2.1k sh Class A Common Stock — Director, See Remarks, 10% owner ~$173k
2026-06-04INSIDERWang David H sold 17.5k sh Class A Common Stock — Director, See Remarks, 10% owner ~$1.49M
2026-06-04INSIDERWang David H sold 11.0k sh Class A Common Stock — Director, See Remarks, 10% owner ~$946k
2026-06-04INSIDERWang David H sold 8.6k sh Class A Common Stock — Director, See Remarks, 10% owner ~$748k
2026-06-04INSIDERWang David H sold 826 sh Class A Common Stock — Director, See Remarks, 10% owner ~$73k
2026-06-04INSIDERCheav Sotheara disposed of 13.4k sh Stock Option — See remarks
2026-06-04INSIDERWang David H disposed of 40.0k sh Stock Option — Director, See Remarks, 10% owner
2026-06-03INSIDERWang David H sold 5.8k sh Class A Common Stock — Director, See Remarks, 10% owner ~$540k
2026-06-03INSIDERWang David H sold 1.2k sh Class A Common Stock — Director, See Remarks, 10% owner ~$110k
2026-06-03INSIDERWang David H sold 4.3k sh Class A Common Stock — Director, See Remarks, 10% owner ~$377k
2026-06-03INSIDERWang David H transacted 60.0k sh Class A Common Stock — Director, See Remarks, 10% owner ~$60k
2026-06-03INSIDERWang David H sold 6.3k sh Class A Common Stock — Director, See Remarks, 10% owner ~$560k
2026-06-03INSIDERWang David H sold 32.5k sh Class A Common Stock — Director, See Remarks, 10% owner ~$2.92M
2026-06-03INSIDERWang David H sold 9.9k sh Class A Common Stock — Director, See Remarks, 10% owner ~$901k
2026-06-03INSIDERWang David H disposed of 60.0k sh Stock Option — Director, See Remarks, 10% owner
2026-05-19 00:00 UTCINSIDER6 insider transactions — 2026-05 · net sell $303k 1 derivative
2026-05-19INSIDERDun Haiping sold 1.9k sh Class A Common Stock — Director ~$125k
2026-05-19INSIDERDun Haiping transacted 5.0k sh Class A Common Stock — Director ~$28k
2026-05-19INSIDERDun Haiping sold 1.3k sh Class A Common Stock — Director ~$85k
2026-05-19INSIDERDun Haiping disposed of 5.0k sh Stock Option — Director
2026-05-13INSIDERWang David H acquired 6.2k sh Restricted Stock Units — Director, See Remarks, 10% owner
Showing the 40 most recent of 61 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage